Dysregulated expression of monoacylglycerol lipase is a marker for anti-diabetic drug metformin-targeted therapy to correct impaired neurogenesis and spatial memory in Alzheimer's disease
Charvi Syal, Jayasankar Kosaraju, Laura K. Hamilton, Anne Aumont, Alphonse Chu, Sailendra Nath Sarma, Jacob Thomas, Matthew Seegobin, F. Jeffrey Dilworth, Ling He, Fredric E. Wondisford, Robert Zimmermann, Martin Parent, Karl J. L. Fernandes, Jing Wang
Abstract
Our findings set the stage for development of a clinical protocol where Mgll would serve as a biomarker in early stages of AD to identify potential metformin-responsive AD patients to restore their neurogenesis and spatial memory.
Topics & Concepts
Monoacylglycerol lipaseNeurogenesisMetforminMedicineDrugDiseaseDiabetes mellitusPharmacologyDrug-naïveNeuroscienceInternal medicineEndocrinologyPsychologyEndocannabinoid systemReceptorMetabolism, Diabetes, and CancerNatural Antidiabetic Agents StudiesDiet and metabolism studies